Apocrine sweat gland disorder

This Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…

This phase 3 trial tests the drug lutikizumab against a placebo in about 1400 adults and teens with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and abscesses. Participants receive weekly shots for 16 weeks, then continue on differen…

This phase 3 trial is testing the long-term safety of bimekizumab, a drug that targets inflammation, in 658 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful boils. Participants who completed a previous study will receive bimek…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This study follows 435 adults with moderate to severe hidradenitis suppurativa (a painful skin condition) who are taking secukinumab. Researchers want to see how doctors adjust the dose over two years and how well the treatment controls symptoms like abscesses and pain. The goal …

This study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 adults and teens who completed an earlier sonelokimab study will receive the drug for an e…

This phase 3 study tests an oral drug called remibrutinib in 565 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. Participants receive one of two doses of remibrutinib or a placebo for 68 weeks. The main goal is to see …

This phase 3 trial tests an oral drug called remibrutinib in 588 people with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition causing painful lumps. The study compares two doses of the drug against a placebo over 68 weeks. The main goal is to see if the …

This phase II trial is testing whether a combination of talimogene laherparepvec (a modified herpes virus that infects and kills cancer cells) and nivolumab (an immunotherapy drug) can shrink tumors in people with rare skin cancers or lymphomas that haven't responded to standard …

This study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers wi…

This study follows 107 adults in Russia with moderate to severe hidradenitis suppurativa (a chronic skin condition causing painful lumps) who are taking secukinumab as part of their normal care. Researchers will track how many patients see a 55% reduction in disease severity over…

This study looks at the long-term safety and effectiveness of the drug povorcitinib for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. Participants have already completed 54 weeks of treatment in earlier studies. The goal is to monitor sid…

This study looks at whether secukinumab can keep hidradenitis suppurativa (a painful skin condition) under control over the long term. It includes 703 adults who already completed a year of treatment with secukinumab. Researchers will measure how long the response lasts and monit…

This early-stage trial tests a single dose of a new biologic drug, SBT777101, in 24 adults with moderate-to-severe hidradenitis suppurativa (a chronic skin condition causing painful abscesses and tunnels). The main goal is to check safety and side effects at increasing dose level…

This study tests whether anifrolumab, an antibody drug, can reduce skin abscesses and nodules in people with hidradenitis suppurativa (HS). Fifteen adults with moderate-to-severe HS will receive the drug intravenously over 24 weeks. The main goal is to see if at least half of par…

This phase 2 trial tests an investigational drug called lutikizumab (ABT-981) in about 210 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing lumps and abscesses. The main study includes people who have already tried and failed anti-TNF…

This study tests five different investigational drugs (iscalimab, LYS006, MAS825, remibrutinib, and ianalumab) in 248 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. The main goal is to see if these drugs reduce abscesses a…

This study tests a new drug called tulisokibart in 147 people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. Participants are randomly assigned to receive either the drug or a placebo, and researchers will check if the drug reduc…

This study tests a new drug called eltrekibart in 352 adults with moderate-to-severe hidradenitis suppurativa (HS), a painful skin condition causing abscesses and inflammation. Participants receive either the drug or a placebo for about 62 weeks. The goal is to find a safe and ef…

This study looks at how satisfied people with moderate to severe hidradenitis suppurativa (HS) are with a new medication called secukinumab, and how it affects their quality of life. About 48 adults in the UAE who are just starting secukinumab will fill out questionnaires over a …

This study looks at whether a simple home exercise program can improve strength, endurance, and quality of life for people with hidradenitis suppurativa (HS), a painful skin condition. Researchers will have 86 adults with HS follow a video-guided exercise routine 3-4 days a week.…

This study tests whether a special 1726nm laser can safely reduce the painful bumps and inflammation caused by hidradenitis suppurativa (HS). Eight adults with mild to moderate HS will receive laser treatment on affected areas like armpits or groin. The main goal is to see if at …

This study planned to test a fractional ablative erbium laser on scarring caused by hidradenitis suppurativa (HS) in the armpit area. It was designed for adults with mild HS activity and visible scars. However, the trial was withdrawn before enrolling any participants, so no resu…

This study aimed to see if Botulinum Toxin-A (Botox) could help people with hidradenitis suppurativa, a painful skin condition. It planned to enroll adults with active armpit lesions of similar severity on both sides. However, the study was withdrawn before any participants were …

This study planned to test whether gentian violet, a common purple antiseptic, could reduce redness, drainage, and pain in people with hidradenitis suppurativa (HS). Participants would have applied the treatment once and returned a month later to report changes. However, the stud…

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …

This study follows 192 adults with hidradenitis suppurativa (a painful skin condition) who are starting secukinumab as part of their normal care. Researchers will ask patients to rate their pain, oozing, and bad smell after 12 months. The goal is to understand how the drug affect…

This study looks at whether artificial intelligence (AI) can match a dermatologist's diagnosis when a general practitioner sends in photos and questions about a patient's skin condition. Researchers will compare the AI's diagnosis to the dermatologist's for about 1000 adults. The…